|
|
Other links at Articles > Diabetes and Endocrinology |
| 3. |
Safety Study Finds Glargine Not Associated With Retinopathy
|
|
|
The safety of the insulin analog glargine (Lantus, Sanofi-Aventis, Paris) was demonstrated in a 5-year post-marketing evaluation of the drug, in which there was no evidence of an increased risk of retinopathy with long-term glargine use. Reuters Health Information
|
| 5. |
An Overview of Incretin Clinical Trials
|
|
|
This article reviews many of the key incretin clinical trials, with a focus on the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors compared with placebo and other glucose-lowering agents used as comparators.
|
|
|
